Evidence map›Paper›PMID 30071516›Full record

ArticleAmerican journal of nephrology2018

Effect of Anti-Hypertensive Medication History on Arteriovenous Fistula Maturation Outcomes.

Ke Wang, Leila R Zelnick, Peter B Imrey, Ian H deBoer, Jonathan Himmelfarb, Michael D Allon, Alfred K Cheung, Laura M Dember, Prabir Roy-Chaudhury, Miguel A Vazquez and 5 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of nephrology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 9 institutions in 2 countries.

Ke WangDepartment of Medicine, Kidney Research Institute, University of Washington, Seattle, Washington, USA.
Leila R ZelnickDepartment of Medicine, Kidney Research Institute, University of Washington, Seattle, Washington, USA.
Peter B ImreyDepartment of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Ian H deBoerDepartment of Medicine, Kidney Research Institute, University of Washington, Seattle, Washington, USA.
Jonathan HimmelfarbDepartment of Medicine, Kidney Research Institute, University of Washington, Seattle, Washington, USA.
Michael D AllonDivision of Nephrology, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, USA.
Alfred K CheungDivision of Nephrology and Hypertension, Salt Lake City, Utah, USA.
Laura M DemberRenal-Electrolyte and Hypertension Division, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Prabir Roy-ChaudhuryDivision of Nephrology, University of Arizona Health Sciences and Banner University Medical Center, Tucson, Arizona, USA.
Miguel A VazquezDivision of Nephrology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
John W KusekDivision of Kidney, Urologic and Hematologic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland, USA.
Harold I FeldmanRenal-Electrolyte and Hypertension Division, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Gerald J BeckDepartment of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Bryan KestenbaumDepartment of Medicine, Kidney Research Institute, University of Washington, Seattle, Washington, USA.
the Hemodialysis Fistula Maturation Study Group
University of Washington · USUniversity of Pennsylvania · USCase Western Reserve University · USCleveland Clinic Lerner College of Medicine · USNational Institute of Diabetes and Digestive and Kidney Diseases · USSouthern Arizona VA Health Care System · USThe University of Texas Southwestern Medical Center · USUniversity of Alabama at Birmingham · USUniversity of Utah · US

Funding

Hemodialysis Fistula Maturation Consortium Data Coordinating CenterU01DK082236 · NIDDK · CLEVELAND CLINIC LERNER COM-CWRU · PI BECK, GERALD J · 2008 to 2013
$7.6M
RESEARCH TRAINING IN RENAL DISEASET32DK007467 · NIDDK · UNIVERSITY OF WASHINGTON · PI BANSAL, NISHA, KESTENBAUM, BRYAN R · 1986 to 2023
$5.1M
Vascular Structure and Function in Arteriovenous Fistula MaturationU01DK082179 · NIDDK · UNIVERSITY OF WASHINGTON · PI HIMMELFARB, JONATHAN · 2008 to 2012
$2.5M
Determinants of Hemodialysis AV Fistula MaturationU01DK082232 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI DEMBER, LAURA M · 2008 to 2012
$2.4M
Modulation of the Hemodynamic Factors Associated with AVF MaturationU01DK082189 · NIDDK · UNIVERSITY OF FLORIDA · PI HUBER, THOMAS S · 2008 to 2012
$1.8M
Anatomic and functional predictors of arteriovenous fistula maturationU01DK082240 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI VAZQUEZ, MIGUEL A · 2008 to 2012
$1.8M
Maturation of Hemodialysis Arteriovenous FistulasU01DK082222 · NIDDK · UNIVERSITY OF UTAH · PI CHEUNG, ALFRED K · 2008 to 2012
$1.8M
Clinical, Hemodynamic and Biological Markers of AV Fistula MaturationU01DK082218 · NIDDK · UNIVERSITY OF CINCINNATI · PI ROY-CHAUDHURY, PRABIR · 2008 to 2012
$1.7M
Mineral metabolism disturbances and arteriovenous fistula maturationR01DK094891 · NIDDK · UNIVERSITY OF WASHINGTON · PI KESTENBAUM, BRYAN R · 2012 to 2014
$930k
Midcareer Investigator Award: Metabolic Complications of Chronic Kidney DiseaseK24DK103986 · NIDDK · UNIVERSITY OF WASHINGTON · PI KESTENBAUM, BRYAN R · 2016 to 2020
$637k
NIDDK NIH HHS K24 DK103986NIDDK NIH HHS R01 DK094891NIDDK NIH HHS T32 DK007467NIDDK NIH HHS U01 DK082179NIDDK NIH HHS U01 DK082189NIDDK NIH HHS U01 DK082218NIDDK NIH HHS U01 DK082222NIDDK NIH HHS U01 DK082232NIDDK NIH HHS U01 DK082236NIDDK NIH HHS U01 DK082240
6 · The paper itself

Abstract

backgroundThe arteriovenous fistula (AVF) is the preferred vascular access for hemodialysis. However, approximately half of AVFs fail to mature. The use of angiotensin converting enzyme inhibitors (ACE-Is), angiotensin receptor blockers (ARBs), and calcium channel blockers (CCBs) exerts favorable endothelial effects and may promote AVF maturation. We tested associations of ACE-I and ARBs, CCBs, beta-blockers, and diuretics with the maturation of newly created AVFs.

methodsWe evaluated 602 participants from the Hemodialysis Fistula Maturation Study, a multi-center, prospective cohort study of AVF maturation. We ascertained the use of each medication class within 45 days of AVF creation surgery. We defined maturation outcomes by clinical use within 9 months of surgery or 4 weeks of initiating hemodialysis.

resultsUnassisted AVF maturation failure without intervention occurred in 54.0% of participants, and overall AVF maturation failure (with or without intervention) occurred in 30.1%. After covariate adjustment, CCB use was associated with a 25% lower risk of overall AVF maturation failure (95% CI 3%-41% lower) but a non-significant 10% lower risk of unassisted maturation failure (95% CI 23% lower to 5% higher). ACE-I/ARB, beta-blocker, and diuretic use was not significantly associated with AVF maturation outcomes. None of the antihypertensive medication classes were associated with changes in AVF diameter or blood flow over 6 weeks following surgery.

conclusionsCCB use may be associated with a lower risk of overall AVF maturation failure. Further studies are needed to determine whether CCBs might play a causal role in improving AVF maturation outcomes.

Indexed as

AdultAgedAntihypertensive AgentsArteriovenous Shunt, SurgicalFemaleHumansKidney Failure, ChronicMaleMiddle AgedProspective StudiesRenal DialysisTreatment FailureVascular PatencyAntihypertensive AgentsAnti-hypertensive medicationsArteriovenous fistula maturation failureCalcium channel blocker

Identifiers

PMID30071516
PMCPMC6421073
OpenAlexW2886440490

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.